Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone609-510-4718
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees14
Next Earnings DateN/A
OptionableNot Optionable
Aprea Therapeutics (NASDAQ:APRE) Frequently Asked Questions
What is Aprea Therapeutics' stock symbol?
Aprea Therapeutics trades on the NASDAQ under the ticker symbol "APRE."
What price target have analysts set for APRE?
3 analysts have issued 1-year price targets for Aprea Therapeutics' shares. Their forecasts range from $23.00 to $33.00. On average, they anticipate Aprea Therapeutics' share price to reach $26.33 in the next twelve months. This suggests a possible upside of 5.4% from the stock's current price. View Analyst Price Targets for Aprea Therapeutics.
What is the consensus analysts' recommendation for Aprea Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aprea Therapeutics.
Has Aprea Therapeutics been receiving favorable news coverage?
Media coverage about APRE stock has been trending very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aprea Therapeutics earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Aprea Therapeutics.
Who are some of Aprea Therapeutics' key competitors?
Some companies that are related to Aprea Therapeutics include Zogenix (ZGNX), Tricida (TCDA), Apellis Pharmaceuticals (APLS), Prestige Consumer Healthcare (PBH), Xencor (XNCR), Aimmune Therapeutics (AIMT), Pacira Biosciences (PCRX), Ironwood Pharmaceuticals (IRWD), Akcea Therapeutics (AKCA), Heron Therapeutics (HRTX), Insmed (INSM), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Alder Biopharmaceuticals (ALDR) and Turning Point Therapeutics (TPTX).
Who are Aprea Therapeutics' key executives?
Aprea Therapeutics' management team includes the folowing people:
- Mr. Christian S. Schade, Pres, CEO & Director (Age 58)
- Mr. Scott M. Coiante, Sr. VP & CFO (Age 52)
- Dr. Lars Abrahmsen, Sr. VP & Chief Scientific Officer (Age 61)
- Dr. Gregory A. Korbel, VP of Bus. Devel. (Age 43)
- Dr. Eyal C. Attar, Sr. VP & Chief Medical Officer (Age 49)
When did Aprea Therapeutics IPO?
(APRE) raised $52 million in an IPO on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO.
When does the company's lock-up period expire?
Aprea Therapeutics' lock-up period expires on Tuesday, March 31st. Aprea Therapeutics had issued 5,666,667 shares in its public offering on October 3rd. The total size of the offering was $85,000,005 based on an initial share price of $15.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.
How do I buy shares of Aprea Therapeutics?
Shares of APRE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aprea Therapeutics' stock price today?
One share of APRE stock can currently be purchased for approximately $24.99.
How big of a company is Aprea Therapeutics?
What is Aprea Therapeutics' official website?
How can I contact Aprea Therapeutics?
Aprea Therapeutics' mailing address is 535 BOYLSTON STREET, BOSTON MA, 02116. The company can be reached via phone at 609-510-4718 or via email at [email protected]
MarketBeat Community Rating for Aprea Therapeutics (NASDAQ APRE)
MarketBeat's community ratings are surveys of what our community members think about Aprea Therapeutics and other stocks. Vote "Outperform" if you believe APRE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APRE will underperform the S&P 500 over the long term. You may vote once every thirty days.
